AbbVie's new endometriosis drug to cost $10K per year

The Food and Drug Administration on Tuesday approved AbbVie's gonadotropin-releasing hormone (GnRH) antagonist elagolix, giving a green light to the first oral treatment for moderate-to-severe endometriosis pain in over a decade.